Glucagon-Like Peptide Ii

Summary

Glucagon-Like Peptide Ii (CHEMBL4297958) is a phase-3 clinical-stage protein; indicated across 2 conditions including short bowel syndrome.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Protein
• Indications: 2 conditions
• Clinical trials: 16

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297958
Name	Glucagon-Like Peptide Ii
Type	Protein
Max phase	3

Also known as: Glp-2, Glp-2 (human), Glucagon-like peptide 2, Glucagon-like peptide ii, GLUCAGON-LIKE PEPTIDE II

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 disease in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
short bowel syndrome	1	MONDO:0015183	MONDO:0015183

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 16.

Phase distribution

Phase	Trials
Not specified	13
PHASE3	1
PHASE1/PHASE2	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01958775	PHASE3	COMPLETED	Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2
NCT01573286	PHASE1/PHASE2	TERMINATED	Safety and Dosing Study of Glucagon-like Peptide 2 (GLP-2) in Infants and Children With Intestinal Failure
NCT03682172	EARLY_PHASE1	COMPLETED	Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects
NCT00273000	Not specified	UNKNOWN	The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans
NCT00673751	Not specified	UNKNOWN	Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome
NCT00732602	Not specified	COMPLETED	The Effects of GIP and GLP-2 on the Secretion of Glucagon in Patients With Type 1 Diabetes
NCT03159741	Not specified	COMPLETED	Investigation of GLP-2 Mechanism of Action (GA-8)
NCT03573934	Not specified	COMPLETED	Gut Hormones and Bone Remodeling in Humans (KS-2)
NCT03574064	Not specified	COMPLETED	Effects of Gut Peptides on Bone Remodeling
NCT03728959	Not specified	COMPLETED	Effects of a Liquid Meal and Gut Hormones (GIP and GLP-2) on Bone Remodeling in Participants With Hypoparathyroidism.
NCT03867656	Not specified	COMPLETED	Effects of Gut Peptides on Bone Remodeling. KS-4-Diabetes-19
NCT03954873	Not specified	COMPLETED	Glucagon-like Peptide 2 - a Glucose Dependent Glucagonotropic Hormone?
NCT04651868	Not specified	COMPLETED	The Effect of Exogenous Glucagon-like Peptide 2 on Cholecystokinin-induced Gallbladder Emptying
NCT05181150	Not specified	UNKNOWN	Gut Peptides and Bone Remodeling in Individuals With Spinal Cord Injury
NCT06194955	Not specified	COMPLETED	The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function
NCT07254988	Not specified	TERMINATED	Gut Peptides and Bone Remodeling in Children With Neuromuscular Disorders

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).